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Abstract
Background: Treatment of complicated skin and skin structure infection (cSSSI) places a tremendous burden
on the health care system. Understanding relative resource utilization associated with different antimicrobials is
important for decision making by patients, health care providers, and payers.
Methods: The authors conducted an open-label, pragmatic, randomized (1:1) clinical study (N = 250) to compare
the effectiveness of daptomycin with that of vancomycin for treatment of patients hospitalized with cSSSI caused
by suspected or documented methicillin-resistant Staphylococcus aureus infection. The primary study end point was
infection-related length of stay (IRLOS). Secondary end points included health care resource utilization, cost, clinical
response, and patient-reported outcomes. Patient assessments were performed daily until the end of antibiotic
therapy or until hospital discharge, and at 14 days and 30 days after discharge.
Results: No difference was found for IRLOS, total LOS, and total inpatient cost between cohorts. Hospital LOS
contributed 85.9 % to the total hospitalization cost, compared with 6.4 % for drug costs. Daptomycin showed a
nonsignificant trend toward a higher clinical success rate, compared with vancomycin, at treatment days 2 and 3.
In the multivariate analyses, vancomycin was associated with a lower likelihood of day 2 clinical success (odds ratio
[OR] = 0.498, 95 % confidence interval [CI], 0.249–0.997; P < 0.05).
Conclusion: This study did not provide conclusive evidence of the superiority of one treatment over the other
in terms of clinical, economic, or patient outcomes. The data suggest that physician and patient preference,
rather than drug acquisition cost, should be the primary driver of initial antibiotic selection for hospitalized
patients with cSSSI.
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Background
Phase 3, international, multicenter, randomized, double-
blind, comparative clinical trials are considered the gold
standard for establishing efficacy of antibiotics used for
treatment of patients with complicated skin and skin
structure infection (cSSSI). Although “efficacy” is estab-
lished in this study design, it is often difficult to generate
quantitative economic or “effectiveness” inferences be-
tween treatments in such trials. Making the leap from
the comparative efficacy to the comparative effectiveness
of an antibiotic used to treat cSSSI is complex and chal-
lenging. For example, studies have clearly shown that
hospital length of stay (LOS) is the primary driver of the
cost of treating patients with cSSSI [1, 2]. However, it is
difficult to make direct LOS comparisons from registra-
tional trials because of their structured nature and ex-
plicit requirements (i.e., fixed duration of therapy, lack
of an oral step-down therapy option during the primary
treatment period). Furthermore, evaluating comparative
effectiveness requires relaxation of certain parameters
included in the design of traditional randomized clin-
ical trials (RCTs), such as patient inclusion and exclu-
sion criteria, monitoring, and restrictions on the use of
both the experimental intervention and the comparator
agent [3, 4].
Comparative effectiveness evaluations also require the
assessment of end points relevant to payers (such as re-
source utilization and cost) or to patients (such as qual-
ity of life, productivity, and the need for follow-up care)
that generally are not considered by the U.S. Food and
Drug Administration (FDA) as part of the marketing ap-
proval process. Likewise, health care providers might be
interested in clinical end points that differ from those
suggested by FDA guidance documents for a particular
therapeutic area. With these considerations in mind, we
conducted an open-label, pragmatic RCT (PRCT) to as-
sess the comparative effectiveness of two commonly used
medications for cSSSI treatment—daptomycin and vanco-
mycin—with the objective of determining a number of
outcomes measures relevant to patients, providers, and
payers, such as health cost and clinical success.
Methods
Study design and sites
This was a real-world, prospective, open-label, multicenter
study conducted from September 2011 through October
2012. The study was conducted at 36 sites (including aca-
demic and nonacademic) in the United States. No specific
site characteristics, investigator criteria, or prior experi-
ence with vancomycin or daptomycin were necessary;
however, vancomycin and daptomycin treatment was to
be consistent with local practice. All patients provided
written informed consent in accordance with local guide-
lines for studies involving human subjects. The study was
conducted in accordance with the 2008 Declaration of
Helsinki. Institutional review board (IRB) or ethics com-
mittee approval was obtained at each participating center
or from a central IRB (Additional file 1). The sections
below broadly follow the 10 PRECIS domains proposed by
Thorpe et al. [4] to describe aspects of the study that were
more pragmatic and more explanatory.
Participant eligibility criteria
In keeping with pragmatic trial principles, minimal in-
clusion criteria were used to identify patients for whom
vancomycin or daptomycin would be the initial treat-
ment choice. To be eligible for the study, patients had to
be at least 18 years of age and hospitalized for compli-
cated SSSI (cellulitis, cutaneous abscess, wound infec-
tion, and burns) caused by suspected or documented
methicillin-resistant Staphylococcus aureus (MRSA) in-
fection that necessitated intravenous (IV) antibiotics for
an anticipated 3 to 14 days of inpatient treatment deter-
mined based on physician clinical experience.
Additionally, patients must have had at least three
of the following clinical signs and symptoms associ-
ated with cSSSI: pain and tenderness with palpation,
elevated temperature (>37.5 °C [99.5 °F] oral or >38 °C
[100.2 °F] rectal); elevated white blood cell (WBC) count
(>10 × 109/L); swelling and/or induration or erythema; or
purulent or seropurulent drainage or discharge. Enroll-
ment within 24 h of hospital admission was necessary. Ex-
clusion criteria were similar to those used in phase 3
clinical trials of daptomycin for management of cSSSI [5];
these included presence of bacteremia, osteomyelitis, sep-
tic arthritis, or endocarditis at the time of enrollment; re-
quirement for curative surgery (e.g., amputation); and use
of systemic antibacterial therapy for the infection for >
24 h within the 48 h preceding the start of administration
of study drug, unless the infection Gram-positive patho-
gen was resistant in vitro to the therapy, or the therapy
was administered for 3 or more days with either worsen-
ing or no improvement in the infection.
Experimental and comparison intervention flexibility
Patients were randomly assigned (1:1) to receive IV vanco-
mycin or IV daptomycin using a computer-generated cen-
tralized randomization schedule. Vancomycin is widely
used as initial cSSSI treatment and, therefore, was chosen
as the comparator [6]. Investigators were advised to
administer daptomycin 4 mg/kg once daily, consistent
with product labeling [7]. To mirror the range of current
clinical practices, vancomycin was dosed at the investiga-
tor’s discretion according to institutional protocol. Only
the first study drug dose was required by the protocol; all
subsequent care decisions were at the discretion of the
treating physician and local hospital practice, including
when to discontinue treatment, whether to convert from
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IV therapy to oral therapy, and the length of therapy. No
restrictions were imposed regarding concomitant medica-
tions, adjunctive procedures, or other therapy.
Follow-up intensity
Study assessments were performed at screening; at base-
line; daily until the end of cSSSI therapy (including
therapy-related adverse event treatment); or at hospital
discharge, whichever occurred first. Assessments were
also performed at hospital discharge and by telephone
interview 14 days and 30 days (±3 days) after hospital dis-
charge. Daily assessments included patient-reported out-
comes (described in Trial Secondary End Points), serious
adverse events, clinical response, clinician statement of
reason for continued hospitalization (if applicable), and
study drug dose. Patients receiving vancomycin were also
assessed each day to determine whether and when the
therapeutic trough level of vancomycin was reached. To
reflect the range of current clinical practices, vancomycin
levels were obtained and therapeutic drug monitoring was
performed at the investigator’s discretion according to in-
stitutional protocol.
At discharge, information describing medical resource
utilization during hospitalization, including tests, proce-
dures, and number of days in specific wards, was collected
from the patient medical record. Follow-up telephone
interviews included patient-reported outcomes, continued
antibiotic therapy and other medical resource utilization,
infection status, and out-of-pocket expenses and time
missed from work for patients and caregivers.
Trial primary outcome
The primary study end point was infection-related length
of stay (IRLOS), because it is objective, easily reproducible,
and relevant to the patient, providers, and payers. IRLOS
was defined as the number of hours of hospitalization as-
sociated with cSSSI management, beginning at study drug
initiation and ending at discontinuation of all antibiotic
therapy for cSSSI or therapy for antibiotic-related adverse
events or at hospital discharge, whichever occurred first.
The criteria that determined patient discharge date and
time are listed below. However, in order to maintain the
pragmatic nature of the trial, the discharge eligibility cri-
teria were not specified in the protocol and it was left to
the discretion of the treating physician and local institu-
tional practices.
 If a patient was switched to another treatment
after study antibiotic stopped, the IRLOS would
continue until the end date of the second
medication.
 If the patient experienced an adverse event (AE), the
treatment-completion date and time for that AE was
recorded as the IRLOS end.
 If the patient finished the treatment before hospital
discharge, the end date and time of last dose of
vancomycin or daptomycin was the IRLOS end.
 If the patient was still receiving cSSSI treatment at
discharge, then the IRLOS would be the same as the
total LOS.
Analysis of primary outcome
The primary analytic sample (PAS) included all patients
with data available to calculate the primary end point
(IRLOS). Data were collected in hours and the results
were converted to days for ease of interpretation. The
PAS excluded patients who discontinued from the study
before discharge, those who left the hospital against
medical advice, and others for whom a discharge assess-
ment could not be completed.
Trial secondary end points
Secondary end points included inpatient medical resource
use during initial hospitalization (adjunctive procedures,
radiologic and laboratory tests, hospital ward unit), total
LOS, cost, and clinical response (cure, improvement, no
improvement, or failure). Total length of stay was mea-
sured in hours and was analyzed by a fixed-effects model
with terms for treatment and the confounding variables.
Secondary end points also included the following patient-
reported outcomes: pain (as rated by the Brief Pain Inven-
tory [Short Form]) [8]; infection status (“improved a lot,”
“improved moderately,” “improved a little,” “no change,”
“worsened a little,” “worsened moderately,” or “worsened
a lot”) as measured by the Patient Global Impression of
Improvement (PGI-I) scale, and quality of life (as rated by
the EuroQol 5 Dimensions, 5 Level [EQ-5D-5 L] multiat-
tribute questionnaire) [9].
Cost
Costs were estimated from the payer perspective and
included direct medical inpatient and outpatient costs.
Direct medical costs were based on health resource
utilization. To estimate cost of care, unit cost data were
obtained from sources external to the study and assigned
to corresponding medical resource utilization observed
within the trial. Hospital ward costs were applied hourly.
General medicine/surgical and intensive care unit costs
were estimated via administrative claims using the Optum
Research Database (http://www.optum.com/life-sciences/
develop-evidence/data-assets.html). Costs for other ward
types were not available in the administrative claims data.
The average daily cost observed among a similar sample
of patients from the Healthcare Cost and Utilization
Project (HCUP) [10], adjusted using a payment-to-cost
ratio of 1.34 [11], was used as a proxy for other ward
costs. The unadjusted average daily cost observed in the
HCUP sample was used as a sensitivity analysis.
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Vancomycin trough monitoring was estimated using
Current Procedural Terminology (CPT) code 80202.
Pharmacy, nursing, or other personnel costs related to
vancomycin trough monitoring or dose changes were
not included in the analysis. For the primary analysis,
acquisition costs for study drug and other antibiotics
administered during hospitalization were estimated
using wholesale acquisition cost (WAC) and attributed
the cost of a full vial for partial vial use of daptomycin.
Daptomycin was “costed” at $342.31 per 500 mg;
vancomycin was costed at $6.13 per gram. As a sensi-
tivity analysis, drug costs were estimated by average
wholesale price (AWP) and assumed no waste. (Full
results, including outpatient, work loss, and out-of-pocket
cost, are available from the authors by request.)
Statistical methods
Sample size
The sample size estimate was based on the primary end
point. Based on antibiotic-related LOS from daptomycin
clinical trials (data on file) and published literature [12],
the expected mean difference in LOS between daptomy-
cin and vancomycin was estimated at approximately
1.5 days (standard deviation [SD], 4.0 days). Assuming
equal sample sizes and two-sided significance testing
with α = 0.05 and 1 – β = 0.80, it was estimated that 224
patients (112 per group) would be necessary to detect a
difference of 1.5 days. A total of 250 patients (125 per
group) were to be enrolled to account for expected study
attrition of 10 %.
Statistical analysis
All descriptive analyses were conducted using the PAS.
Descriptive statistics for continuous variables are re-
ported as mean, SD, median, or range, as appropriate.
All categorical variables were summarized by frequency
and percentage. Patient-reported outcomes of pain and
quality of life were assessed as changes from baseline
using last observation carried forward methodology.
Time to clinical success (cure or improvement) was
modeled using Cox proportional hazards. For bivariate
analyses, categorical variables were compared using the
Fisher exact test, and continuous variables were com-
pared using the Student t or Mann–Whitney test.
Stratified analyses were performed to determine whether
the infection type and pathogen modified the relationship
between treatment and outcomes. Multivariate analyses
were performed to quantify the association between treat-
ment and each outcome after adjustment for potential
confounding variables. All potential confounding variables
(baseline covariates associated with outcomes at P < 0.2)
were included at model entry and were retained in the
model if the associated P value was < 0.05. All potential
confounding variables were analyzed descriptively and
clinically to determine appropriate inclusion in the multi-
variate analyses of IRLOS, total LOS, total inpatient cost,
and clinical success.
Potentially confounding variables included in each
model were patient demographics (age, sex, and body
mass index [BMI] ≥ 35), presence of a primary care pro-
vider (yes/no), baseline Charlson comorbidity score (con-
tinuous), baseline blood culture (yes/no), prior all-cause
hospitalizations (0, 1, 2, or more), systemic inflammatory
response syndrome (SIRS) (count of four conditions),
leukocytosis (WBC > 12 × 109/L, yes/no), elevated cre-
atinine level (>132.6 μmol/L, yes/no), infection type,
vancomycin use within previous 48 h (yes/no), treat-
ment switch ≥ 24 h preceding discharge (yes/no) or
within 24 h of discharge (yes/no), documented MRSA
(yes/no), documented Gram-negative infection (yes/
no), baseline patient-reported pain score (continuous),
patient eagerness for discharge (definitely go home, def-
initely stay, or unsure), lower extremity infection site
(yes/no), cSSSI infection in the preceding 6 months
(yes/no), and infectious disease physician as site investi-
gator (yes/no). Multivariate analyses were also con-
trolled for clustering by study site. The continuous
outcomes (IRLOS, total LOS, and total inpatient cost)
were fitted to a generalized linear model with gamma
distribution and log link to account for their skewed
distribution. Clinical success was modeled via logistic
regression. The multivariate analysis sample (MVAS)
included all patients from the PAS with available data
on all covariates. All hypothesis testing was performed
at the 5 % significance level. Values of test statistics
were considered statistically significant when P ≤ 0.05.
Results
Patients
Of 250 enrolled patients, data were available for 224
(daptomycin, n = 118; vancomycin, n = 106) to calculate
the primary end point of IRLOS; therefore, they com-
prised the PAS (Table 1). There were no significant dif-
ferences between the cohorts at baseline; however, a
lower percentage of patients was designated as Hispanic/
Latino in the daptomycin group than in the vancomycin
group (12.7 % vs. 22.6 %, respectively; P = 0.05, data not
shown). Overall, the patient population included slightly
more males than females and was primarily white; mean
(SD) BMI was 33.2 (10.3) in daptomycin patients and
34.2 (11.7) in vancomycin patients. Approximately 50 %
of the total cohort had been hospitalized during the
prior year and 33 % had a previous cSSSI within the pre-
ceding 6 months. Fifty percent of patients were receiving
vancomycin at the time of enrollment or within 48 h
before enrollment. The majority of patients had compli-
cated cellulitis (65.2 %), major cutaneous abscess (40.6 %),
or wound infection (15.2 %).
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Baseline data were incomplete for three patients in the
daptomycin group. Therefore, the MVAS consisted of 115
patients in the daptomycin group and 106 patients in the
vancomycin group. After hospital discharge, 183 patients
(daptomycin, n = 92; vancomycin, n = 91) responded to the
14-day interview and 196 patients (daptomycin, n = 101;
vancomycin, n = 95) responded to the 30-day interview.
Health economic outcomes
For the primary end point of IRLOS, there was no sig-
nificant difference between the daptomycin and vanco-
mycin arms for either PAS or MVAS (Table 2). The LOS
in one (0.9 %) daptomycin and two (1.9 %) vancomycin
patients extended beyond management of cSSSI because
of treatment of adverse events that resulted from treat-
ment of the cSSSI. In addition, neither total LOS nor total
inpatient cost was significantly different between cohorts
under unadjusted or adjusted conditions. In our base case
analysis, assuming WAC and waste of partial daptomycin
vials, mean total inpatient cost was $9641 for the dapto-
mycin arm and $9083 for the vancomycin arm. Hospital
LOS contributed 85.9 % to the total hospitalization cost,
compared with 6.4 % for drug costs.
In the sensitivity analysis, in which AWP was used
and there was no assumed drug wasted, the mean total
inpatient cost was $9409 for daptomycin and $9106
for vancomycin. Hospital LOS was the primary driver
of cost in both treatment arms (Fig. 1). The drug cost
for daptomycin was significantly greater than that of
vancomycin. Conversely, daptomycin was associated
with lower laboratory and radiologic test costs than
vancomycin (P < 0.001 for both comparisons; Fig. 1).
No statistically significant difference in IRLOS, LOS,
and total inpatient cost between the daptomycin and
vancomycin cohorts was seen when these parameters
were analyzed by infection type or pathogen (Table 3).
Clinical success and patient-reported outcomes
Because all patients reached clinical success (i.e., improve-
ment or cure) by the end of their inpatient stay, clinical
success was defined for analysis purposes as success
within 2 to 3 days of randomization. A greater proportion
of daptomycin-treated than vancomycin-treated patients
achieved clinical success by day 2 and day 3 (Fig. 2a). Al-
though the unadjusted differences in clinical success were
not significant, logistic regression analysis showed that
vancomycin treatment, relative to daptomycin treatment,
was associated with a decreased chance of achieving clin-
ical success within 2 days (odds ratio [OR] = 0.498; 95 %
confidence interval [CI], 0.249–0.997; P = 0.049). Signifi-
cant variables in the 2-day response included count of
SIRS (P = 0.041), Gram-negative infection (P = 0.006), and
baseline vancomycin use (P = 0.031). Similarly, clinical
success rates were not significantly different within 2 and
3 days of treatment when analyzed by infection type
(Fig. 2b) or pathogen (Fig. 2c).
Table 1 Baseline demographics and clinical characteristics of






Male, n (%) 64 (54.2) 57 (53.8)
Age, y, mean (SD) 47.2 (15.2) 50.0 (13.5)
Weight, kg, mean (SD) 97.1 (29.8) 97.4 (30.4)
BMI, mean (SD) 33.2 (10.3) 34.2 (11.7)
Clinical characteristics
Hospitalizations in preceding year, n (%) 61 (51.7) 49 (46.2)
Patients with cSSSI in preceding
6 months, n (%)
36 (30.5) 37 (34.9)
Charlson comorbidity score, mean (SD) 1.1 (1.6) 1.1 (1.3)
Patients with diabetes, n (%) 34 (28.8) 37 (34.9)
SIRS symptoms, n (%)
Temperature > 38 °C or > 100.4 °F 19 (16.1) 12 (11.3)
Heart rate > 90 beats/minute 54 (45.8) 43 (40.6)
Tachypnea (> 20 breaths/minute) 12 (10.2) 6 (5.7)
Blood pressure < 90/50 mmHg 5 (4.2) 1 (0.9)
WBC count > 12 × 109/L 61 (51.7) 41 (38.7)
Blood urea nitrogen > 8.9 mmol/L 12 (10.2) 6 (5.7)
Creatinine > 132.6 μmol/L 12 (10.2) 9 (8.5)
Patient-reported pain score, mean (SD) 6.6 (3.0) 6.9 (3.2)
Vancomycin use at enrollment or within
48 h before randomization, n (%)
65 (55.1) 50 (47.1)
Baseline blood culture, n (%) 82 (69.5) 76 (71.7)
Gram-negative infection, n (%)a 11 (16.7) 7 (10.8)
cSSSI diagnosis, n (%)
Complicated cellulitisb 81 (68.6) 65 (61.3)
Major cutaneous abscess 45 (38.1) 46 (43.4)
Wound infection 18 (15.3) 16 (15.1)
Erysipelas 0 (0) 0 (0)
Diabetic ulcer 2 (1.7) 5 (4.7)
Nondiabetic ulcer (stasis ulcer/
decubitus ulcer)
2 (1.7) 3 (2.8)
Bite wound 1 (0.9) 1 (0.9)
Burn wound 0 (0) 0 (0)
Otherc 2 (1.7) 3 (2.8)
BMI body mass index, cSSSI complicated skin and skin structure infection, SD
standard deviation, SIRS systemic inflammatory response syndrome, WBC
white blood cell
aBased on the number of patients with primary skin infection lesion culture
obtained at baseline (daptomycin, n = 66; vancomycin, n = 65)
bDefined as cellulitis that requires hospitalization and treatment with IV
antibiotics suspected or documented to be caused by MRSA
c“Other” infection sites include groin, axillae, breast, back, suprapubic region,
genitalia, anterior perineum, face, hand, and preseptal region
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No notable differences in patient-reported outcomes
(pain, health-related quality of life, or infection status) by
group were observed. Patient assessments of infection im-
provement mirrored clinical assessments: nearly 80 % of pa-
tients reported “a little,” “moderately,” or “a lot” improved
by day 2. Patient-reported quality of life and pain scores also
showed rapid improvement in both treatment groups.
Discussion
The purpose of this trial was to examine therapy in pa-
tients deemed by the investigator to need IV anti-MRSA
antibiotic treatment. Patients whom the investigator de-
cided could be treated with an oral agent would not fall
within the inclusion criteria for this study. In addition, this
study was not designed to examine if inpatient length of
stay could be reduced by the administration of oral agents
(i.e., trimethoprim/sulfamethoxazole or clindamycin), al-
though switching to other antibiotic was accounted for in
the IRLOS calculation.
Overall, we observed comparable and relatively short
IRLOS and total LOS across study groups, which trans-
lated into similar total inpatient costs. In our study, LOS
contributed 85.9 % to the total cost of hospitalization,
compared with 6.4 % for drug costs. From an administrative
perspective, there might be a tendency for institutions to
weigh drug acquisition cost as a major determinant of for-
mulary inclusion once safety and efficacy concerns are met.
This is understandable because pharmacy expenditure is a
highly visible budget component. However, overall inpatient
costs in this study were equivalent, despite large differences
in acquisition costs between the two drugs. This finding
highlights the importance of LOS rather than drug cost as
the primary component of total inpatient cost in cSSSI.
Although we did not find significant differences in
IRLOS or total inpatient cost, we observed significantly
greater odds of achieving clinical success by day 2 in the
daptomycin group than in the vancomycin group and
positive trends in the daptomycin group for key patient
subgroups based on infection site and pathogen. This
finding might be due to a potential for partial crossover
in patients who received vancomycin for less than 24 h,
though an analysis of factors contributing to the early
clinical response was not included in the study design.
By day 3, more than 80 % of patients in both groups
achieved clinical success, yet average LOS was about 4 days
whether patients achieved clinical success by day 2 or day
Table 2 Health economic outcomes
Outcome Unadjusted (PAS) Adjusted (MVAS)
Daptomycin (n = 118) Vancomycin (n = 106) P value Rate ratiob P value
IRLOS, hours, mean (SD) 91.5 (57.8) 93.2 (60.8) 0.823 1.002 (0.844–1.191) 0.979
Total LOS, hours, mean (SD) 98.5 (77.0) 101.2 (72.1) 0.785 1.018 (0.861–1.204) 0.833
Total inpatient cost, 2012 US$, mean (SD)a 9641 (6683) 9083 (5855) 0.509 0.940 (0.803–1.101) 0.442
IRLOS infection-related length of stay, LOS length of stay, MVAS multivariate analytic sample, PAS primary analytic sample, SD standard deviation
aWholesale acquisition cost estimates using “waste” algorithm
bRate ratio reflects effect of vancomycin relative to daptomycin on outcome of interest. Ratios reported as mean (95 % confidence interval)
Fig. 1 Mean inpatient costs by components. Drug cost calculation assumes waste of partial daptomycin vials. P = NS for all. Ward/unit cost
was defined as the cost care in a particular unit or ward. Adjunctive procedures included incision/drainage, surgical debridement/excision,
amputation, device removal/replacement, wound specialist services, and physical therapy. Radiology tests included radiography, medical
resonance imaging, ultrasound, and computed tomography. WAC, wholesale acquisition cost
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3. The unblinded study design may also have impacted the
assessment of clinical response, and is a limitation of the
study. Our findings suggest an opportunity to further de-
crease LOS, which is the primary driver of health care
costs for patients with cSSSI. One approach would be to
speed the transition to outpatient treatment for patients
who are responding and who do not require treatment in
the hospital. The optimal discharge plan is likely to vary
widely depending on hospital, patient, and environmental
factors but could include a form of outpatient parenteral
antibiotic therapy for certain patients who show early clin-
ical success. A focus on facilitating appropriate discharge
based on clinical response should have a positive benefit
on overall health care use, even if resulting LOS reduc-
tions are modest.
The economic outcomes of this study are subject to
several limitations that should be considered when inter-
preting the results. First, because cultures were not ob-
tained for all patients, we cannot rule out an imbalance
in methicillin-susceptible Staphylococcus aureus (MSSA)
that favors the daptomycin arm, which might have af-
fected our findings because vancomycin has been associ-
ated with increased risk for treatment failure in MSSA
infections compared with other antibiotics [13]. In
addition, we relied largely on an administrative database
of commercial health plans to estimate hospital costs.
Such costs naturally will vary by hospital. Another po-
tential limitation of the study is that drug acquisition
costs are expected to vary by institution. We used the
WAC for the base case analysis as our best estimate of
the cost that most hospitals pay for inpatient medica-
tion. Use of the AWP increased the total drug cost in
both groups, particularly the daptomycin group. Both
WAC- and AWP-based cost estimates were subject to
two methods of daptomycin costing. In the base case,
we assumed that partial doses of daptomycin were
wasted (e.g., a patient needing 600 mg of daptomycin
would be assigned two vials for costing purposes). A less
conservative approach assumed no wasting of daptomy-
cin, which decreased the difference in estimated cost
compared with that of vancomycin. Combining the unit
cost options and the possible waste provided best-case
(WAC, no waste) and worst-case (AWP, with waste) es-
timates of additional inpatient costs attributable to dap-
tomycin of $235 and $665, respectively.
In the current study, patients in the vancomycin cohort
were more likely than those in the daptomycin cohort to
have a dose adjustment. The cost of dose adjustments in
terms of nursing or pharmacy time or consultation were
not included in the analysis; only the nursing time and la-
boratory cost associated with trough measurement were
included. Many institutions use a pharmacy consultant
or other service to monitor vancomycin patients, and
daptomycin use might result in a cost offset because of
the lack of a requirement for therapeutic drug monitor-
ing [14, 15]. Costs or outcomes associated with anti-
biotic stewardship or the development of resistance
were not assessed in this study.
Finally, the current study was not powered to detect
differences in cost, and none of the cost outcomes dif-
fered statistically between the two study groups, with the
exception of drug and laboratory costs. The premise for
a 1.5-day difference in LOS was based on previous dap-
tomycin clinical trial data and single-center studies that
Table 3 Health economic outcomes by infection type and pathogen (unadjusted)a–c
Abscess Cellulitis Wound
By infection typed Daptomycin Vancomycin Daptomycin Vancomycin Daptomycin Vancomycin
(n = 40) (n = 42) (n = 54) (n = 44) (n = 17) (n = 16)
IRLOS, hours, mean (SD) 83.8 (53.8) 102.1 (75.4) 97.3 (61.5) 80.2 (43.5) 94.4 (63.4) 109.0 (59.0)
Total LOS, hours, mean (SD) 94.8 (102.2) 105.6 (75.2) 101.7 (64.4) 85.1 (56.6) 103.0 (58.9) 139.3 (94.3)
Total inpatient cost, 2012 US$, mean (SD)a 9515 (8501) 9432 (5955) 9871 (5805) 7415 (4750) 9814 (5927) 13,101 (7025)
Staphylococcus aureuse MRSA MSSA
By pathogen Daptomycin Vancomycin Daptomycin Vancomycin Daptomycin Vancomycin
(n = 58) (n = 43) (n = 39) (n = 27) (n = 14) (n = 10)
IRLOS, hours, mean (SD) 98.4 (64.5) 101.2 (69.4) 98.5 (67.0) 85.9 (51.8) 84.5 (43.6) 136.2 (95.5)
Total LOS, hours, mean (SD) 109.0 (95.9) 105.4 (69.3) 111.3 (108.5) 92.3 (53.7) 93.0 (54.2) 136.2 (95.5)
Total inpatient cost, 2012 US$, mean (SD)a 10,508 (8109) 9604 (5691) 10,692 (9171) 8854 (4119) 8967 (4084) 11,308 (8345)
IRLOS infection-related length of stay, LOS length of stay, MRSA methicillin-resistant Staphylococcus aureus, MSSA methicillin-susceptible Staphylococcus aureus, SD
standard deviation, WAC wholesale acquisition cost
aMultivariate analysis sample of 115 daptomycin and 106 vancomycin patients
bWAC cost estimates using “waste” algorithm
cThe P value was nonsignificant for all comparisons between daptomycin and vancomycin
dFour daptomycin and four vancomycin patients had other infection types
eIncludes known S. aureus infection for those patients with a culture; please note 5 daptomycin and 6 vancomycin patients were dropped from the MRSA/MSSA
subgroup analyses mostly due to missing data
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reported an average LOS of approximately 4 to 8 days
(data on file, Merck & Co., Inc.) [12]. In the intervening
period, LOS for cSSSI has steadily decreased [10]. Al-
though the intent of our study was to enroll patients
with an anticipated LOS of at least 3 days, only 54.9 and
58.0 % of patients met that criterion ex post facto for
IRLOS and total LOS, respectively.
Conclusions
This pragmatic clinical trial of daptomycin compared with
vancomycin for management of cSSSI caused by suspected
or documented MRSA, similar to many PRCTs [16], did not
provide conclusive evidence of the superiority of one treat-
ment over the other in terms of clinical, patient, or eco-
nomic outcomes. However, it did identify the potential for
continued reduction in LOS with more rapid discharge of
patients who showed clinical improvement, an idea that de-
serves further study. The trial also highlights the importance
of evaluating the total cost of inpatient care rather than fo-
cusing solely on drug acquisition cost. In summary, the data
suggest that health care provider and patient preference, ra-
ther than drug acquisition cost, should be the primary driver
of initial antibiotic selection for hospitalized patients with
cSSSI. Physician and patient preferences can be driven by
many factors, including but not limited to physician experi-
ence, dosing frequency, laboratory monitoring, and the po-
tential for earlier discharge.
Additional file
Additional file 1: Daptomycin Pragmatic Skin Trial IRB and
Participating Center List. (DOCX 18 kb)
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Fig. 2 Proportion of patients achieving clinical success by day 2 and
day 3: overall (a), by infection type (b), and by pathogen (c). Clinical
success was defined as improvement or cure. a Odds ratio (OR) for
vancomycin compared with daptomycin. b Clinical success rates by
infection type, excluding the 4 daptomycin and 4 vancomycin patients
with “other” infection types. c Clinical success rates by pathogen, includr
known S. aureus infection for those patients with a culture. MRSA,
methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible
Staphylococcus aureus. See Table 3 for sample sizes
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